Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Spackman

Pain Medicine Meridian, ID Medical Doctor

NPI 1386887032 CMS profile 1086090

360 E Montvue Dr, Suite 100, Meridian, ID 83642

Open in the dashboard

General payments

$3,173

195 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Spackman of Meridian, ID is reported in the CMS Open Payments database as having received $3,173 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $461 52
2024 General $544 63
2023 General $236 23
2022 General $1,338 5
2021 General $292 25
2020 General $194 20
2019 General $107 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Spackman
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Michael Spackman were reported at $461. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Michael Spackman Pain Medicine median Middle half National median
2019 $107 $409 $115–$1,311 $163
2020 $194 $214 $66–$666 $114
2021 $292 $299 $84–$899 $132
2022 $1,338 $335 $103–$1,149 $149
2023 $236 $376 $114–$1,228 $160
2024 $544 $387 $115–$1,173 $164
2025 $461 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $1,280 1 payment
  2. Medtronic, Inc. $833 115 payments
  3. Abbott Laboratories $582 56 payments
  4. Spinefrontier, Inc. $87 1 payment
  5. Biodelivery Sciences International, Inc. $68 4 payments
  6. Collegium Pharmaceutical, Inc. $66 4 payments
  7. Medtronic USA, Inc. $56 4 payments
  8. Dexcom, Inc. $38 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $34 2 payments
  10. Lilly USA, LLC $32 2 payments
  11. Other $96 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,893 194 payments
  2. Travel and Lodging $1,280 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $446 59 payments
  2. INCEPTIV $190 28 payments
  3. Proclaim IPG $136 15 payments
  4. VANTA ADAPTIVESTIM $132 24 payments
  5. ETERNA $132 12 payments
  6. Proclaim Family of SCS IPGs $123 15 payments
  7. SIJFuse $87 1 payment
  8. NanoFUSE $87 1 payment
  9. Inspan $87 1 payment
  10. FacetFuse $87 1 payment
  11. Other $686 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,597

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$76,350

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

40.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 73 $22,026
Oxycontin Oxycodone Hcl Brand 41 $19,270
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 312 $7,404
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 185 $6,586
Pregabalin Generic 123 $6,303
Morphine Sulfate Er Morphine Sulfate Brand 87 $2,903
Fentanyl Generic 25 $2,534
Gabapentin Generic 149 $2,232
Baclofen Generic 169 $2,186
Oxycodone Hcl Generic 69 $1,689

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$102,399

Of which drugs: $668

Medicare patients

256

Average age 73

Services billed

4,540

142 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Diabetes 29%
Depression 29%
Osteoporosis 21%
Chronic kidney disease 20%
Ischemic heart disease 18%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 44 555 $414
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 119 2,981 $255

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record